There are barriers to a pathways-type approach to medicine, which can help oncologists provide structure to complex data from multiple inputs at the point of care, according to a speaker at the 2015 AVBCC annual meeting.
Improvement of side-effect management includes proactive education, emotional support, and frequent, comprehensive follow-up and monitoring throughout treatment for patients and their families.
Future studies should seek to determine whether and to what extent cancer care is impacted by the PPACA, as a recent study found that patients with testicular, stomach, and cervical cancers are more likely to be uninsured.
If your practice or cancer center receives, handles, stores, compounds, dispenses, administers, or disposes of hazardous drugs, you may soon be affected by the US Pharmacopeial Convention’s General Chapter 800 Hazardous Drugs—Handling in Healthcare Settings (USP 800). It will affect different practices in different ways, depending on how it is enforced as well as the agency or organization that may choose to enforce it.
According to a recent study, 63.6% of oncologists surveyed favor the establishment of an independent panel of health experts to decide which treatments Medicare will pay for based on a cost-benefit analysis. Less than 50% of patients and members of the general public think this is a good idea. The United Kingdom’s National Institute for Health and Care Excellence (NICE) is one model for such a panel.
Three of the main factors currently influencing patient support services are population health management, patient engagement, and shifting perspectives in biopharma, Tracy Foster told a roomful of attendees recently at the 2015 Patient Assistance & Access Programs meeting held in Baltimore, MD.
Recently retired and looking back over my decades in the workforce, I see gender issues once again gaining strength. I was raised to believe there were no gender barriers or limitations, and most of what I have seen in my youth and working years has supported that. Yet significant events stand in stark contrast, leaving an indelible mark in my mind and a subtle reminder of a different era.
It is a fact of life. The current tax system rewards taxpayers who are aggressive with their deductions. To find out what people are deducting, we undertook an informal survey of many of our colleagues who are certified public accountants. We found that a handful of deductions show up repeatedly on the tax returns of those taxpayers who tend to be very aggressive with their deductions. How aggressive are you with the deductions you claim on your income tax return each year? Below we discuss some of the more common deductions we have found.
On April 14, 2015, after years of uncertainty and 17 short-term “doc fix” patches to prevent severe annual cuts to physician reimbursement payments, Congress approved the Medicare Access and CHIP Reauthorization Act (MACRA), bringing an end to the Medicare sustainable growth rate (SGR). This bipartisan, bicameral compromise will provide physicians with the predictability in payments needed to continue to provide high-quality cancer care, while transitioning over a 10-year period to a new Medicare reimbursement system.
The following clinical trials are currently recruiting patients with multiple myeloma for inclusion in several investigations. Each trial description includes the NLM Identifier to use as a reference with ClinicalTrials.gov.
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
Similar to myelofibrosis and essential thrombocythemia, polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm. Polycythemia vera is characterized by the clonal stem-cell proliferation of red blood cells, white blood cells, and platelets. Increased red blood cell mass results in the hyperviscosity of the blood, an increased risk for thrombosis, poor quality of life, and a shortened life expectancy.
The following sections will assist healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of lung cancer.
Results 1 - 12 of 12